Medial EarlySign’s Co-founder Ori Geva and CEO Dr. Jeremy Orr describe the company’s development, from its origin as a Silicon Valley-like startup operating out of an Israeli garage, to its growth and deployment of clinical algorithmic solutions with leading health systems in both Israel and the U.S.
“The company was launched in 2013,” Geva told Globes. “After we had already begun to recognize the benefits of artificial intelligence in the e-commerce and financial services spaces, we realized the potential for this technology to revolutionize our lives if we applied it to the health field. We have already begun working with initial U.S. healthcare system clients and are bringing on new customers who have not traditionally been technological innovators.”
Geva discussed the company’s focus on chronic illnesses like prediabetes and diabetes, and other high-burden conditions including lower GI disorders and flu complications. He explained that “we had to do this, because if the health care system does not treat chronic illnesses before they become severe, the whole system will collapse.”
CEO Dr. Orr, a U.S.-based physician who is also the company’s Chief Medical Officer, explained how Medial EarlySign is “attracting interest not only from hospitals and healthcare systems, but also from other parties like diagnostic companies.”
Click here to read the full article